08 February 2010
Kristin Paulick took a moment to welcome us to the 2010 ePharma Summit.
08 February 2010
Welcome to the first day of the ePharma Summit. We're excited to kick off our two day conference with a reception from Within3. We're looking forward to the next two days at the ePharma Summit!Stay tuned to this blog for live coverage of the 9th Annual ePharma Summit!
08 February 2010
The Astelin (azelastine HCl nasal spray) letter, citing a waiting room sign for the allergy drug, DDMAC objects that "in contrast to the consumer-friendly claims on the sign, some of the risk information that is disclosed (i.e., 'somnolence' and 'rhinitis') is presented in medical terminology that is not likely to be understood by consumers." Similarly, the citation of a patient brochure for OraVerse states that: "While the patient brochure presents efficacy claims for OraVerse in language that is easily understandable to consumers, it presents risk information using complex medical terminology that is not likely to be comprehended by the same audience." Both citations rely on the prominence standard: FDA considers ads to be misleading "if they fail to present information about the risks associated with a drug with a prominence and readability reasonably comparable with the presentation of information relating to the effectiveness of the drug." What does this mean for the drug industry and patients?
08 February 2010
As reported over at minyanville.com (" Sign of the Times? Cosmetic Surgery Is Back "): According to a survey done by MEDACorp, plastic surgery and cosmetic procedures were up during the fourth quarter of 2009 for the first time since the downturn began in 2007. The survey encompassed facial injectibles, breast implants, laser procedures, and Latisse for eyelash growth.
08 February 2010
Top line results per the research report; 1. Consumers are overwhelmed with the amount of health information on the Internet and therefore they are most likely to start their searches for information at trusted sites like Web MD. 2
08 February 2010
There's a reason why Eli Lilly doesn't do any TV advertising for Zyprexa and it has nothing to do with continuing litigation. It has to do with the fact that Zyprexa is not a product that should be prescribed a lot because it requires patients to be closely monitored by their physicians to ensure they don't gain a lot of weight and become diabetic.
08 February 2010
Well, I have no particular need to make azo-linked compounds (see this morning's post for one reason!). And I have to say, although it's mechanistically interesting, I definitely feel no desire to make them by combining a hydroperoxide and a diazonium salt in one pot. This is not a moment destined to take its place alongside the legendary invention of the chocolate/peanut butter cup.
08 February 2010
In a Notice of Violation letter to Lilly ( see here ), FDA cited two videos supposedly submitted by patients who take ADCIRCA, Lilly's drug approved for the treatment of Pulmonary Arterial Hypertension (PAH). The patient videos present statements made by Adcirca users, “Traci” and “Carolyn" who make the following claims among others: “I can walk, and stairs don’t bother me after Adcirca treatment . .
08 February 2010
On January 29th new documents appeared in the FDA's docket that has been devised to collect commentary after the November 12-13 Part 15 meeting on social media and the Internet and medical product marketing.
08 February 2010
The future of the life sciences industry relies on creating a multi-channel marketing strategy, which includes combining traditional practices with new marketing channels, such as the internet and social media sites.
